Surrozen, inc.SRZN.US Overview
SRZN Overall Performance
SRZN AI Analysis & Strategy
SRZN Recent Performance
-1.88%
Surrozen, inc.
0.81%
Avg of Sector
-1.14%
S&P500
SRZN PowerScanner
SRZN Key Information
SRZN Valuation Metrics
SRZN Earnings Table
SRZN Profile
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.